Learn more about
our groundbreaking tests
and their potential to
transform cancer screening,
follow-up and monitoring at
rgcc-international.com.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

Shaping the cancer care paradigm

At RGCC, we strongly believe that personalized medicine is the future of cancer treatment. To improve the chances of successful treatment and survival, RGCC services help you to make informed decisions and formulate effective treatment plans.

Our team of scientists and medical experts conducts precise and reliable genetic tests to study cancer cells at all levels, as well as new therapeutic approaches.

RGCC REGIONAL OFFICE

RGCC Southeast Asia
2 Venture Drive #09-27 Vision Exchange
Singapore 608526
info@rgcc-seasia.com
+65 8084 6380

LABORATORY FACILITIES

RGCC International GmbH
Lindenstrasse 14
6340 Baar, Switzerland

Welmedis GmbH
Schönenbergstrasse 12
8820 Wädenswil, Switzerland

RGCC S.A.
Industrial Area of Florina
53100 Florina, Greece

RGCC Central Europe
Biozentrum, Weinbergweg 22
06120 Halle (Saale), Germany

RGCC India PVT LTD
Plot no 55, Road no 5
Aleap Industrial Area
Gajularamaram, Hyderabad, India

Member of
RGCC GROUP

A cancer therapy personalized for you

ChemoSNiP test

ChemoSNiP

When a drug is administered to the body, the body responds to the drug itself. Not every patient responds to chemotherapy identically. ChemoSNiP looks at how our body responds to a chemotherapy agent. This tells us whether our body removes the agent rapidly, reducing its effectiveness or detoxing poorly, resulting in higher chances of toxicity. ChemoSNiP allows a clinician to analyze how a patient's body reacts to the specific drug.

How does ChemoSNiP work?

- ✓ The human body commonly has variants that make us different from one another. These variants are called SNPs or single nucleotide polymorphisms. SNPs can make us respond differently to chemicals (drugs) when administered to the body.
- ✓ These are also responsible for the metabolism / detoxification of cytostatic or targeted drugs used in cancer therapy.
- ✓ ChemoSNiP examines these potential SNPs which affect how our body manages a drug, providing an exclusion criterion for chemotherapy that either may not work well or end up being excessively toxic to the body. It thus helps clinicians make superior personalized decisions on medication would work best and even modify dosages to prevent excessive toxicity.

ChemoSNiP
- looks for → Single Nucleotide Polymorphisms
- helps → Clinicians to choose personalized treatment

How does ChemoSNiP help?

- ✓ The test result provides the doctors with valuable insight into identifying the drug that can be activated and then metabolized by patient's body.
- ✓ ChemoSNiP provides information to the treating oncologist indicating whether a particular chemotherapy would be highly toxic (the patient is unable to detox and clear the chemotheraphy) or ineffective (as the patient would clear off the chemotheraphy rapidly compared to the normal population) to a particular patient.
- ✓ Through personalized analysis, the test enables us to determine the treatment that is most suitable for a patient.

Why choose the ChemoSNiP test?

With molecular biology-based assays, ChemoSNiP has the effectiveness to locate and analyze the SNPs.

The study of SNPs helps indicate which chemotherapeutic treatments would benefit the patient with the least risk of adverse side effects.

Provides insights and personalized analysis of drugs and treatments for each patient.

Test details

Sample type
Whole peripheral blood sample or swab sample

Sample size
10-15ml of whole peripheral blood or 2 swabs

Cancer type
Applicable for all cancer types

Analysis period
Approx. 6–8 working days

Final results
10–12 days after sample delivery

Scan this QR code

Take your first step to get personalized cancer care.